Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EPIX |
---|---|---|
09:32 ET | 293 | 6.25 |
10:21 ET | 300 | 6.1062 |
10:42 ET | 500 | 6.15 |
10:55 ET | 100 | 6.19 |
11:08 ET | 100 | 6.14 |
11:11 ET | 200 | 6.11 |
11:15 ET | 600 | 6.0507 |
11:24 ET | 815 | 6.128 |
11:31 ET | 1631 | 6.0901 |
11:51 ET | 100 | 6.15 |
12:03 ET | 200 | 6.06 |
12:05 ET | 300 | 6.05 |
12:09 ET | 300 | 6.06 |
12:12 ET | 300 | 6.05 |
12:16 ET | 400 | 6.09 |
12:18 ET | 200 | 6.04 |
12:21 ET | 300 | 6.04 |
12:23 ET | 300 | 6 |
12:27 ET | 200 | 6 |
12:30 ET | 373 | 6 |
12:32 ET | 463 | 6.16 |
12:34 ET | 100 | 6.02 |
12:36 ET | 100 | 6 |
12:56 ET | 500 | 6 |
01:01 ET | 100 | 5.978 |
01:39 ET | 300 | 5.9862 |
02:00 ET | 300 | 5.99 |
02:36 ET | 100 | 6.05 |
02:54 ET | 2600 | 6.03 |
03:18 ET | 1745 | 5.91 |
03:20 ET | 400 | 5.98 |
03:30 ET | 730 | 5.91 |
03:32 ET | 107 | 5.86 |
03:36 ET | 1000 | 5.8899 |
03:45 ET | 300 | 5.83 |
03:48 ET | 100 | 5.85 |
03:52 ET | 300 | 5.85 |
03:54 ET | 100 | 5.86 |
03:56 ET | 100 | 5.82 |
03:57 ET | 2300 | 5.835 |
03:59 ET | 19600 | 5.7 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ESSA Pharma Inc | 252.2M | -9.1x | --- |
Design Therapeutics Inc | 249.1M | -4.2x | --- |
XBiotech Inc | 256.7M | -8.3x | --- |
Pyxis Oncology Inc | 244.3M | -3.0x | --- |
Monte Rosa Therapeutics Inc | 261.7M | -2.1x | --- |
Quantum-Si Inc | 255.2M | -2.8x | --- |
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $252.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.77 |
EPS | $-0.63 |
Book Value | $3.30 |
P/E Ratio | -9.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.